We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editor's Correspondence |

Virologic Response Associated With a Change in Protease Inhibitor Therapy

David Butcher, MD; Jeffrey Greene, MD; Phong Duong, PharmD; Leona Markson, ScD
Arch Intern Med. 2000;160(3):393-394. doi:.
Text Size: A A A
Published online


In the report by Guardiola and colleagues,1 a switch in protease inhibitor (PI) therapy for reasons other than therapeutic failure occurred in 74% of patients who were treated with PI-based regimens. The therapeutic strategy in these patients needs careful assessment before PI changes, since the patients may be put at greater risk for therapeutic failure after therapy change.

Figure 1 shows the virologic response in 14 patients who had a switch in PI after having achieved viral RNA suppression (viral RNA load <400 copies per milliliter) compared with 28 patients who continued to receive a successful regimen. Patients from 2 clinics were included in this retrospective chart review if they were treated with an indinavir sulfate regimen for at least 6 months and had 2 viral RNA measures below detection while receiving indinavir-combination therapy.2 From this group, patients were further identified for the switch group if their PI therapy had changed from indinavir to nelfinavir mesylate and if they had at least 1 viral RNA measurement after the PI switch (t0). Patients who continued to receive indinavir regimens constituted the comparison group. Two comparison patients per nelfinavir switch patient were randomly selected and matched for status of PI use prior to indinavir treatment and start date of indinavir treatment. Each comparison patient was assigned a date that allowed a time receiving indinavir equal to the time receiving indinavir of the matched patient who switched to nelfinavir. Patients in both groups had to have evidence of viral RNA suppression in the 3 months prior to t0. In the nelfinavir switch patients without a documented reason for PI change, the patients also had to have documented undetectable viral RNA (viral RNA load <400 copies per milliliter) within 4 weeks after the switch, indicating that the PI change was not a result of therapeutic failure. In Kaplan-Meier analysis, the last viral RNA measure available for each patient was defined as censored if viral RNA was undetectable and no further observations were available or as indicative of failure if the viral RNA load was greater than 400 copies per milliliter.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption

Kaplan-Meier plot of the proportion of 14 patients with viral RNA loads less than 400 copies per milliliter after a switch in protease inhibitor therapy compared with 28 patients who continued to receive a successful regimen. t0 indicates the time protease inhibitor therapy was switched.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

4 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed
The Biological Agent